Table 5.
Associations of air pollutants with risk of all-cause mortality in individuals with IBD, CD, and UC in the UK Biobank study, mean follow-up of 12 y.
Air pollutants in quartiles () | IBD () | CD () | UC () | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cases/person-years | HR (95% CI)a | p-Value | HR (95% CI)b | p-Valuec | Cases/person-years | HR (95% CI)b | p-Value | Cases/person-years | HR (95% CI)b | p-Value | |
Per IQR (15.6) | — | 1.12 (1.03, 1.21) | 0.008 | 1.10 (1.01, 1.20) | 0.036 | — | 1.04 (0.89, 1.21) | 0.637 | — | 1.14 (1.01, 1.29) | 0.030 |
Q1 () | 82/13,835 | Ref | — | Ref | — | 28/4,425 | Ref | — | 54/9,360 | Ref | — |
Q2 () | 118/13,701 | 1.51 (1.14, 2.01) | 0.004 | 1.44 (1.08, 1.91) | 0.012 | 41/4,165 | 1.57 (0.96, 2.54) | 0.070 | 77/9,510 | 1.37 (0.97, 1.95) | 0.076 |
Q3 () | 114/13,580 | 1.49 (1.12, 1.98) | 0.006 | 1.39 (1.04, 1.85) | 0.026 | 39/4,422 | 1.33 (0.82, 2.18) | 0.250 | 75/9,013 | 1.41 (0.99, 2.01) | 0.058 |
Q4 (50.4–247.5) | 106/13,788 | 1.53 (1.15, 2.04) | 0.004 | 1.39 (1.04, 1.86) | 0.025 | 36/4,178 | 1.30 (0.79, 2.14) | 0.301 | 70/9,489 | 1.37 (0.95, 1.96) | 0.088 |
p-Trend | — | — | 0.007 | — | 0.049 | — | — | 0.481 | — | — | 0.106 |
Per IQR (10.4) | — | 1.18 (1.06, 1.31) | 0.003 | 1.16 (1.03, 1.29) | 0.010 | — | 1.17 (0.98, 1.41) | 0.079 | — | 1.13 (0.98, 1.30) | 0.091 |
Q1 () | 92/13,825 | Ref | — | Ref | — | 32/4,521 | Ref | — | 60/9,269 | Ref | — |
Q2 () | 110/13,765 | 1.26 (0.95, 1.66) | 0.107 | 1.21 (0.92, 1.60) | 0.178 | 38/4,149 | 1.29 (0.80, 2.07) | 0.290 | 72/9,494 | 1.19 (0.84, 1.68) | 0.319 |
Q3 () | 98/13,822 | 1.13 (0.85, 1.50) | 0.405 | 1.05 (0.79, 1.39) | 0.755 | 29/4,360 | 0.91 (0.55, 1.51) | 0.709 | 69/9,356 | 1.10 (0.77, 1.56) | 0.592 |
Q4 (33.4–86.6) | 120/13,491 | 1.58 (1.20, 2.07) | 0.001 | 1.48 (1.13, 1.95) | 0.005 | 45/4,161 | 1.55 (0.98, 2.46) | 0.059 | 75/9,254 | 1.42 (1.01, 2.00) | 0.045 |
p-Trend | — | — | 0.004 | — | 0.018 | — | — | 0.162 | — | — | 0.079 |
Per IQR (2.3) | — | 1.04 (1.01, 1.06) | 0.003 | 1.15 (1.03, 1.30) | 0.015 | — | 1.26 (1.04, 1.53) | 0.017 | — | 1.08 (0.93, 1.26) | 0.299 |
Q1 () | 93/13,810 | Ref | — | Ref | — | 26/4,245 | Ref | — | 67/9,493 | Ref | — |
Q2 () | 95/13,906 | 1.03 (0.77, 1.37) | 0.854 | 1.01 (0.76, 1.34) | 0.946 | 35/4,546 | 1.34 (0.80, 2.23) | 0.263 | 60/9,278 | 0.87 (0.62, 1.24) | 0.451 |
Q3 () | 121/13,715 | 1.39 (1.06, 1.82) | 0.017 | 1.35 (1.03, 1.76) | 0.032 | 39/4,270 | 1.60 (0.97, 2.65) | 0.067 | 82/9,331 | 1.18 (0.85, 1.64) | 0.317 |
Q4 (20.3–28.6) | 111/13,472 | 1.38 (1.05, 1.82) | 0.022 | 1.34 (1.02, 1.77) | 0.037 | 44/4,130 | 1.84 (1.13, 3.01) | 0.015 | 67/9,272 | 1.12 (0.80, 1.57) | 0.511 |
P-Trend | — | — | 0.004 | — | 0.008 | — | — | 0.011 | — | — | 0.237 |
Per IQR (1.3) | — | 1.02 (1.01, 1.03) | 0.003 | 1.14 (1.02, 1.28) | 0.019 | — | 1.10 (0.91, 1.33) | 0.325 | — | 1.17 (1.01, 1.36) | 0.030 |
Q1 () | 86/13,865 | Ref | Ref | 33/4,508 | Ref | 53/9,284 | Ref | ||||
Q2 () | 120/13,605 | 1.43 (1.09, 1.89) | 0.011 | 1.38 (1.04, 1.82) | 0.023 | 41/4,280 | 1.33 (0.84, 2.12) | 0.223 | 79/9,289 | 1.40 (0.99, 1.98) | 0.059 |
Q3 () | 102/13,650 | 1.25 (0.94, 1.67) | 0.125 | 1.16 (0.87, 1.55) | 0.307 | 32/4,161 | 1.05 (0.64, 1.71) | 0.858 | 70/9,389 | 1.22 (0.85, 1.76) | 0.272 |
Q4 (10.6–20.7) | 112/13,783 | 1.46 (1.10, 1.94) | 0.008 | 1.36 (1.02, 1.80) | 0.035 | 38/4,242 | 1.24 (0.77, 1.98) | 0.377 | 74/9,411 | 1.40 (0.98, 2.00) | 0.062 |
p-Trend | — | — | 0.031 | — | 0.118 | — | — | 0.613 | — | — | 0.140 |
Note: —, no data; BMI, body mass index; CD, Crohn’s disease; CI, confidence interval; HR, hazard ratio; IBD, inflammatory bowel disease; IQR, interquartile range; , nitrogen dioxide; , nitrogen oxides; PM, particulate matter; PM with aerodynamic diameter ; , PM with aerodynamic diameter ; Ref, reference; UC, ulcerative colitis.
Based on Cox proportional model adjusted for age, sex, ethnicity.
Based on Cox proportional model adjusted for age, sex, ethnicity, assessment centers, household income, smoking status, education, BMI, physical activity, healthy diet, alcohol consumption, baseline related surgery history, medication (use of nonsteroidal anti-inflammatory drugs, amino salicylates, corticosteroids, and immunomodulators).
-Value was considered statistically significant.